Other Events ·
Nexalin Technology, Inc. received a notice from Nasdaq on August 14, 2026, indicating it no longer satisfies the…
NXLIWNexalin Technology, Inc.
Nexalin Technology, Inc. received a notice from Nasdaq on August 14, 2026, indicating it no longer satisfies the minimum stockholders' equity requirement of $2,500,000, citing reported equity of $1,519,423 in its June 30, 2026 Form 10-Q. This deficiency adds to a previously issued delisting notice regarding failure to meet the minimum bid price requirement. The company has requested a hearing before a Nasdaq Hearing Panel scheduled for September 1, 2026, to appeal both deficiencies. The filing warns that delisting could materially adversely affect liquidity and capital-raising ability. Nexalin Technology operates in the biotechnology industry, focusing on neuromodulation therapies.